MARKET

DRNA

DRNA

Dicerna
NASDAQ

Real-time Quotes | Nasdaq Last Sale

21.61
+0.22
+1.03%
After Hours: 21.61 0 0.00% 16:19 09/17 EDT
OPEN
21.44
PREV CLOSE
21.39
HIGH
21.63
LOW
20.75
VOLUME
2.18M
TURNOVER
--
52 WEEK HIGH
40.14
52 WEEK LOW
17.76
MARKET CAP
1.68B
P/E (TTM)
-12.6976
1D
5D
1M
3M
1Y
5Y
Busy IPO market this week poised to make 2021 the biggest year ever by proceeds
After a flurry of initial public offering launches last week set the market up for a busy fall for deals, 11 are expected to price this week and raise more than $3 billion in proceeds.
Marketwatch.com · 3d ago
Cathie Wood's ARK Invest Posts Fund Sales For Friday, Sept. 10, 2021: IOVA, NSTG, U, NVDA, TRMB, IRDM, TTD, LC, CLLS, CRBU, DRNA, PSTG, PSTI, NVS, SPR
Iovance Biotherapeutics (IOVA) - 132,377  Nanostring Technologies (NSTG) - 55,617  Unity Software (U) - 138,794  Nvidia (NVDA) - 300 Trimble (TRMB) - 15,880  Iridium
Benzinga · 4d ago
Dicerna to Participate in 16th Annual Citi Biopharma Conference
LEXINGTON, Mass., September 02, 2021--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., Pre...
Business Wire · 09/02 20:05
Dicerna Pharmaceuticals Sponsored Study Titled 'Phase 1 SAD Study of DCR-AUD in Healthy Volunteers' Posted To ClinicalTrials.Gov; Study Not Yet Recruiting
https://clinicaltrials.gov/ct2/show/NCT05021640
Benzinga · 08/25 13:30
Where Dicerna Pharmaceuticals Stands With Analysts
Analysts have provided the following ratings for Dicerna Pharmaceuticals (NASDAQ:DRNA) within the last quarter: Last 30 Days 1 Month Ago
Benzinga · 08/21 16:30
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12)
Benzinga · 08/13 11:43
Dicerna Pharmaceuticals Inc (DRNA) President and CEO Douglas Fambrough Bought $110,500 of Shares
GuruFocus News · 08/11 18:15
Dicerna Pharmaceuticals Sponsored Study Titled 'Nedosiran in Pediatric Patients From Birth to 5 Years of Age With PH and Relatively Intact Renal Function (PHYOX8)' Posted To Clinical Trials Website; Study Not Yet Recruiting
https://clinicaltrials.gov/ct2/show/NCT05001269
Benzinga · 08/11 13:41
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DRNA. Analyze the recent business situations of Dicerna through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DRNA stock price target is 30.89 with a high estimate of 35.00 and a low estimate of 26.00.
EPS
Institutional Holdings
Institutions: 272
Institutional Holdings: 71.92M
% Owned: 92.52%
Shares Outstanding: 77.73M
TypeInstitutionsShares
Increased
62
3.12M
New
44
2.30M
Decreased
64
6.09M
Sold Out
25
1.49M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Chairman/Independent Director
J. Kevin Buchi
President/Chief Executive Officer/Director
Douglas Fambrough
Chief Financial Officer
Douglas Pagan
Chief Operating Officer/Executive Vice President
James Weissman
Executive Vice President/Chief Scientific Officer
Bob Brown
Executive Vice President
Shreeram Aradhye
Other
Robert Ciappenelli
Secretary
Ling Zeng
Independent Director
Stephen Doberstein
Independent Director
Martin Freed
Independent Director
Patrick Gray
Independent Director
Stephen Hoffman
Independent Director
Adam Koppel
Independent Director
Marc Kozin
Independent Director
Anna Protopapas
Independent Director
Cynthia Smith
No Data
About DRNA
Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. It is focused on development of RNAi-based therapeutics using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases and cardiovascular diseases. Its development programs include dacryocystorhinostomy (DCR)-PHXC for the treatment of primary hyperoxaluria (PH), which is in a Phase I clinical trial; DCR-HBVS for the treatment of chronic hepatitis B virus (HBV), which is in a Phase I clinical trial, and a product candidate against a rare liver disease. It also developed a wholly owned clinical candidate, DCR-BCAT, targeting the β-catenin oncogene. DCR-BCAT is delivered by its lipid nanoparticle (LNP) tumor delivery system, EnCore.

Webull offers kinds of Dicerna Pharmaceuticals Inc stock information, including NASDAQ:DRNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DRNA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DRNA stock methods without spending real money on the virtual paper trading platform.